Doctor Laura Michael
Eli Lilly & Co, Indianapolis (United States of America)
Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation
Event: ESC Congress 2023
Topic: Lipid-Lowering Agents
Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates
